WOCKHARDT LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 574.6 INR | +1.45% |
|
+0.73% | +35.03% |
| Apr. 03 | Wockhardt Limited Announces Cessation of Independent Directors | CI |
| Feb. 14 | Wockhardt Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Wockhardt Limited is a pharmaceutical and biotechnology company. The Company's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines. It manufactures a range of dosage forms, including sterile injectables and lyophilized products. The Company offers products in therapeutic areas of dermatology, cosmeceuticals, oncology, medical nutrition, osteoarthritis, pain management, nephrology, cough therapy and diabetology. The Companyâs products across India includes Citawok, Citawok Forte, Citawok Plus, CONSEGNA 30/70 U-200 CART, CONSEGNA R U-200 CART, DARBOTIN PFS, DECDAN, DECDAN B, DECDAN B Injection, DECDAN LITE CREAM, Emrok, Emrok O, Erliso, FOSCHEK-S, Gabawok NT, GLARITUS CART, GLARITUS DISPO, Glimaday, INOGLA, Livatira, GLARITUS CART and VAL 450. It has manufacturing and research facilities in India, United States of America and the United Kingdom and a manufacturing facility in Ireland.
Sector
Pharmaceuticals
Calendar
2024-05-23
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +35.03% | 1.04B | |
| +21.26% | 43.18B | |
| +20.67% | 22.59B | |
| +15.11% | 14.56B | |
| +38.55% | 11.5B | |
| -8.37% | 6.93B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +10.21% | 5.36B | |
| -2.27% | 4.81B |
- Stock Market
- Equities
- WOCKPHARMA Stock
- News Wockhardt Limited
- Wockhardt Widens Consolidated Net Profit in Fiscal Q3
